Skip to main content
NASDAQ:TSRO

Tesaro News Headlines

Notice: This company has been marked as potentially delisted and may not be actively trading.
$74.96
0.00 (0.00 %)
(As of 01/18/2019)
Add
Compare
Today's Range
$74.94
$74.97
50-Day Range N/A
52-Week Range
$23.41
$75.16
Volume1.19 million shs
Average Volume1.97 million shs
Market Capitalization$4.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.38

Headlines

Tesaro (NASDAQ TSRO) News Headlines Today

SourceHeadline
Replimune Appoints Tanya Lewis as Chief Development Operations Officer - StreetInsider.comReplimune Appoints Tanya Lewis as Chief Development Operations Officer - StreetInsider.com
streetinsider.com - May 10 at 9:03 AM
Ovarian Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - Yahoo Finance UKOvarian Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - Yahoo Finance UK
uk.finance.yahoo.com - May 5 at 8:47 AM
Zenas BioPharma Announces New Executive Leadership Appointments - StreetInsider.comZenas BioPharma Announces New Executive Leadership Appointments - StreetInsider.com
streetinsider.com - May 4 at 7:40 PM
Ovarian Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - Yahoo FinanceOvarian Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - Yahoo Finance
finance.yahoo.com - May 4 at 2:40 PM
Helsinn appoints Mary Lynne Hedley to Board of Directors - GlobeNewswireHelsinn appoints Mary Lynne Hedley to Board of Directors - GlobeNewswire
globenewswire.com - April 29 at 9:20 AM
BRIEF-GSK Q1 Adjusted EPS 22.9 Pence - ReutersBRIEF-GSK Q1 Adjusted EPS 22.9 Pence - Reuters
reuters.com - April 28 at 9:14 AM
Anaptysbio (ANAB) Announces European Commission Approves JEMPERLI - StreetInsider.comAnaptysbio (ANAB) Announces European Commission Approves JEMPERLI - StreetInsider.com
streetinsider.com - April 23 at 4:48 PM
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer - StreetInsider.comMagenta Therapeutics Appoints David Nichols as Chief Technical Officer - StreetInsider.com
streetinsider.com - April 20 at 12:52 AM
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer - Yahoo FinanceMagenta Therapeutics Appoints David Nichols as Chief Technical Officer - Yahoo Finance
finance.yahoo.com - April 19 at 9:51 AM
Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors - StreetInsider.comMersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors - StreetInsider.com
streetinsider.com - March 11 at 2:46 PM
Mersana Therapeutics (MRSN) Announces Appointment of Allene Diaz to Board of Directors - StreetInsider.comMersana Therapeutics (MRSN) Announces Appointment of Allene Diaz to Board of Directors - StreetInsider.com
streetinsider.com - March 11 at 9:45 AM
Clear Cell Sarcoma - Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer - ResearchAndMarkets.com - Business WireClear Cell Sarcoma - Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer - ResearchAndMarkets.com - Business Wire
businesswire.com - February 9 at 3:05 PM
Clear Cell Sarcoma - Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer - ResearchAndMarkets.com - Yahoo FinanceClear Cell Sarcoma - Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - February 9 at 10:03 AM
Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio - BloombergGlaxo Aims to Double Blockbusters in Bid to Revive Portfolio - Bloomberg
bloomberg.com - January 12 at 11:32 AM
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula® - GlobeNewswireMyriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula® - GlobeNewswire
globenewswire.com - January 8 at 8:07 AM
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in Chinas National Reimbursement Drug List - StreetInsider.comZai Lab Announces Inclusion of ZEJULA® (Niraparib) in China's National Reimbursement Drug List - StreetInsider.com
streetinsider.com - December 28 at 9:23 PM
Ovarian Cancer Disease Insights and Market Report 2020-2026 Featuring AstraZeneca, Clovis Oncology, Zai Lab, Tesaro, Mersana Therapeutics, GlaxoSmithKline, ImmunoGen, Jiangsu Hengrui Medicine - ResearchAndMarkets.com - Yahoo FinanceOvarian Cancer Disease Insights and Market Report 2020-2026 Featuring AstraZeneca, Clovis Oncology, Zai Lab, Tesaro, Mersana Therapeutics, GlaxoSmithKline, ImmunoGen, Jiangsu Hengrui Medicine - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - December 16 at 2:32 PM
This is how Id invest £1k today to create a passive income and retire early - Motley Fool UKThis is how I'd invest £1k today to create a passive income and retire early - Motley Fool UK
fool.co.uk - December 15 at 8:50 AM
Novavax (NVAX) Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates - StreetInsider.comNovavax (NVAX) Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates - StreetInsider.com
streetinsider.com - November 10 at 3:08 PM
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates - StreetInsider.comNovavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates - StreetInsider.com
streetinsider.com - November 9 at 7:28 PM
Replimune Appoints Tanya Lewis to the Board of Directors - StreetInsider.comReplimune Appoints Tanya Lewis to the Board of Directors - StreetInsider.com
streetinsider.com - October 19 at 5:29 PM
Southwest Pilots Fire Back at Companys Push to Cut Pay - NasdaqSouthwest Pilots Fire Back at Company's Push to Cut Pay - Nasdaq
nasdaq.com - October 12 at 9:32 PM
Why Surface Oncology Stock Soared Today - Motley FoolWhy Surface Oncology Stock Soared Today - Motley Fool
fool.com - October 12 at 9:32 PM
Why Surface Oncology Stock Soared Today - NasdaqWhy Surface Oncology Stock Soared Today - Nasdaq
nasdaq.com - October 12 at 4:31 PM
GlaxoSmithKline: An Unusual Defensive Healthcare Play - Seeking AlphaGlaxoSmithKline: An Unusual Defensive Healthcare Play - Seeking Alpha
seekingalpha.com - October 8 at 11:57 PM
Glaxos Zejula Gets Positive CHMP View for First-Line Setting - NasdaqGlaxo's Zejula Gets Positive CHMP View for First-Line Setting - Nasdaq
nasdaq.com - September 21 at 12:59 PM
Global Preclinical Stage Partnering Deal Terms and Agreements in Pharma and Biotech Directory 2014-2020 - ResearchAndMarkets.com - Business WireGlobal Preclinical Stage Partnering Deal Terms and Agreements in Pharma and Biotech Directory 2014-2020 - ResearchAndMarkets.com - Business Wire
businesswire.com - September 18 at 6:32 PM
European advisory group backs expanded use of Glaxos Zejula - Seeking AlphaEuropean advisory group backs expanded use of Glaxo's Zejula - Seeking Alpha
seekingalpha.com - September 18 at 6:32 PM
Global Pharma and Biotech Preclinical Stage Partnering Deals, Terms and Agreements Report 2014-2020 - GlobeNewswireGlobal Pharma and Biotech Preclinical Stage Partnering Deals, Terms and Agreements Report 2014-2020 - GlobeNewswire
globenewswire.com - September 16 at 1:05 PM
PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel - GlobeNewswirePMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel - GlobeNewswire
globenewswire.com - September 10 at 7:54 AM
PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel - StreetInsider.comPMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel - StreetInsider.com
streetinsider.com - September 8 at 12:37 PM
Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs - StreetInsider.comMersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs - StreetInsider.com
streetinsider.com - August 31 at 9:00 AM
Glaxo Receives EU Approval for Multiple Myeloma Drug Blenrep - Yahoo FinanceGlaxo Receives EU Approval for Multiple Myeloma Drug Blenrep - Yahoo Finance
finance.yahoo.com - August 27 at 1:24 PM
Most Women Treated in New York City for Gynecologic Cancers Are Not at Increased Risk of Death From COVID-19 - Yahoo FinanceMost Women Treated in New York City for Gynecologic Cancers Are Not at Increased Risk of Death From COVID-19 - Yahoo Finance
finance.yahoo.com - July 30 at 7:46 AM
Global Castrate-resistant Prostate Cancer (CRPC) Market 2017-2030 - Epidemiology, Pipeline, Drugs, Reimbursement Scenario, Competitive Intelligence - ResearchAndMarkets.com - Business WireGlobal Castrate-resistant Prostate Cancer (CRPC) Market 2017-2030 - Epidemiology, Pipeline, Drugs, Reimbursement Scenario, Competitive Intelligence - ResearchAndMarkets.com - Business Wire
www.businesswire.com - July 28 at 1:30 PM
Global PARP Inhibitor Market To Grow At A CAGR Of 27.4% Due To Expanding Role Of PARP Inhibitors In Cancer Treatment - GlobeNewswireGlobal PARP Inhibitor Market To Grow At A CAGR Of 27.4% Due To Expanding Role Of PARP Inhibitors In Cancer Treatment - GlobeNewswire
www.globenewswire.com - July 22 at 8:46 AM
GSK shown up by AstraZeneca yet again - Yahoo FinanceGSK shown up by AstraZeneca yet again - Yahoo Finance
finance.yahoo.com - July 20 at 6:49 PM
GSK shown up by AstraZeneca yet again - Financial TimesGSK shown up by AstraZeneca yet again - Financial Times
www.ft.com - July 20 at 1:49 PM
Glaxos Multiple Myeloma Candidate Gets FDA Committee Nod - Yahoo FinanceGlaxo's Multiple Myeloma Candidate Gets FDA Committee Nod - Yahoo Finance
finance.yahoo.com - July 15 at 7:37 PM
Glaxos Multiple Myeloma Candidate Gets FDA Committee Nod - NasdaqGlaxo's Multiple Myeloma Candidate Gets FDA Committee Nod - Nasdaq
www.nasdaq.com - July 15 at 2:36 PM
Forget Cash ISAs. Id buy this FTSE 100 company instead - Yahoo Finance UKForget Cash ISAs. I'd buy this FTSE 100 company instead - Yahoo Finance UK
uk.finance.yahoo.com - July 7 at 2:31 PM
Reata Announces Promotion and New Hires For Key Leadership Roles - GlobeNewswireReata Announces Promotion and New Hires For Key Leadership Roles - GlobeNewswire
www.globenewswire.com - July 7 at 9:31 AM
Cancer Therapeutics & Supportive Care Drugs Market Research Report by Drug Class, by Cancer Type - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswireCancer Therapeutics & Supportive Care Drugs Market Research Report by Drug Class, by Cancer Type - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswire
www.globenewswire.com - June 30 at 12:32 PM
Is GlaxoSmithKline a Great Dividend Stock? - Motley FoolIs GlaxoSmithKline a Great Dividend Stock? - Motley Fool
www.fool.com - June 19 at 9:01 AM
Acceleron Appoints Christopher Hite to its Board of Directors - Business WireAcceleron Appoints Christopher Hite to its Board of Directors - Business Wire
www.businesswire.com - June 5 at 7:29 PM
Acceleron Pharma (XLRN) Announces Christopher Hite to Board - StreetInsider.comAcceleron Pharma (XLRN) Announces Christopher Hite to Board - StreetInsider.com
www.streetinsider.com - June 4 at 6:31 PM
World Market for Next Generation Immune Checkpoint Inhibitors and Stimulators - Forecast and Opportunity Analysis - Yahoo FinanceWorld Market for Next Generation Immune Checkpoint Inhibitors and Stimulators - Forecast and Opportunity Analysis - Yahoo Finance
finance.yahoo.com - June 2 at 1:43 PM
Clovis Oncology Needs a Savior - Yahoo FinanceClovis Oncology Needs a Savior - Yahoo Finance
finance.yahoo.com - May 21 at 10:17 PM
Ovarian Cancer Industry Forecasts to 2029 - Generics to Increase in Total Market Revenue Share from 18% to 25% by 2029, Driven by Loss of Exclusivity Events - GlobeNewswireOvarian Cancer Industry Forecasts to 2029 - Generics to Increase in Total Market Revenue Share from 18% to 25% by 2029, Driven by Loss of Exclusivity Events - GlobeNewswire
www.globenewswire.com - May 15 at 7:47 AM
Global Ovarian Cancer Market Assessment 2019-2029 - Roche Will Continue to Dominate as the Single Largest Player with Approx. 31% of Total Market Revenue in 2029 - Yahoo FinanceGlobal Ovarian Cancer Market Assessment 2019-2029 - Roche Will Continue to Dominate as the Single Largest Player with Approx. 31% of Total Market Revenue in 2029 - Yahoo Finance
finance.yahoo.com - May 14 at 5:30 AM
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.